Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.64 |
| ▸ | JAK1 | P23458 | 7/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | MAPKAPK3 | Q16644 | 3/20 | 0.51 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.51 |
| ▸ | ULK1 | O75385 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 3/20 | 0.48 |
| ▸ | CDK8 | P49336 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17206177 | 0.98 | JAK2 (0.62) | JAK2JAK1PDPK1MAP2K4MAPK1 | |
| SCHEMBL922195 | 0.86 | PDPK1 (0.53) | JAK2JAK1PDPK1MAP2K4MAPK1 | |
| SCHEMBL2671620 | 0.85 | JAK2 (0.49) | JAK2JAK1MAP2K4MAPK1MAPKAPK3 | |
| Hydrochloric Acid SCHEMBL17205412 | 0.84 | PDPK1 (0.51) | JAK2JAK1PDPK1MAP2K4MAPK1 | |
| SCHEMBL4404641 | 0.84 | JAK2 (0.58) | JAK2JAK1PDPK1ULK1CCNC | |
| SCHEMBL3511548 | 0.83 | JAK2 (0.66) | JAK2JAK1PDPK1ULK1KDM4E | |
| SCHEMBL2671070 | 0.82 | MAP2K4 (0.55) | JAK2JAK1MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL13495835 | 0.81 | JAK2 (0.68) | JAK2JAK1PDPK1ULK1CCNC | |
| SCHEMBL8356174 | 0.81 | PRKAG1 (0.52) | JAK2JAK1MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL1145076 | 0.81 | MAP2K4 (0.57) | JAK2JAK1MAP2K4MAPK1MAPKAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849044-B | Triaza-spirodecanones as DDR1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-2623101-B1 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2021-04-21 | — | — | EP | disclosed |
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10858321-B2 | Composition for inducing cell reprogramming | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-08 | — | — | US | disclosed |
| US-10858321-B2 | Composition for inducing cell reprogramming | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-08 | — | — | US | disclosed |
| EP-3134408-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3134408-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2020-08-12 | — | — | EP | disclosed |
| CN-106794172-B | Composition for inducing cell reprogramming | 光州科学技术院 | 2020-03-17 | — | — | CN | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| EP-1765788-B1 | 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES | MERCK PATENT GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| EP-1765788-B1 | 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES | MERCK PATENT GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| EP-1773786-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005123050-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | JAK2 1448/4885JAK1 1291/4885PDPK1 453/4885 |
| US-10858321-B2 | Composition for inducing cell reprogramming | MCL1, IRF3, STING1 | JAK2 1123/4885JAK1 573/4885PDPK1 30/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | JAK2 1448/4885JAK1 1291/4885PDPK1 453/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | JAK2 441/4885JAK1 426/4885PDPK1 2713/4885 |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | F11, TFPI, F12 | JAK2 504/4885JAK1 237/4885PDPK1 3591/4885 |
| US-20070232620-A1 | 3-Aminoindazoles | SGK3, SGK1, SGK2 | JAK2 562/4885JAK1 343/4885PDPK1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.